The Drug Enforcement Administration (DEA) is investigating far more pharmacies than it used to, and it expects more of them than most owners and pharmacists realize. Pharmacies that are committed to their patients but are short-staffed, stretched thin, or working without written documentation procedures are being scrutinized.
The consequences of a DEA investigation, whether it proceeds on an administrative or criminal track, can be severe: immediate disruption to operations, registration suspension or revocation, civil penalties that can reach into the millions of dollars, and personal criminal liability for individual pharmacists and owners. The difference between a routine inspection and a significant enforcement action often comes down to the policies, documentation, and compliance practices a pharmacy has in place before the DEA ever arrives.
Corresponding Responsibility: The Practical Obligation
Under 21 C.F.R. § 1306.04, a controlled substance prescription is valid only if issued for a legitimate medical purpose by a practitioner acting within the usual course of professional practice, and the regulation states that a corresponding responsibility rests with the dispensing pharmacist. That obligation is not satisfied by simply confirming the DEA number, verifying the prescriber’s license, and ensuring the prescription form is complete. Instead, it requires the pharmacist to evaluate the clinical plausibility of each controlled substance prescription and to act on any indication that the prescription may warrant further inquiry.
DEA investigators have developed consistent fact patterns that they treat as indicators requiring resolution before dispensing. These include prescribers whose specialty does not align with the medication or therapeutic category, patients traveling distances that bypass closer pharmacies, cash transactions in the absence of insurance coverage, early refill requests inconsistent with prescribed dosing schedules, and concurrent prescriptions for opioids, benzodiazepines, and skeletal muscle relaxants from the same or multiple prescribers.
No single indicator is necessarily dispositive, but each creates a separate and independent documentation obligation. When a pharmacist identifies a potential red flag and decides to dispense, the record must reflect what the concern was, what steps were taken to address it, who was contacted, what information was received, and how that information resolved the pharmacist’s concern.
How Federal Investigations Begin
DEA Diversion Investigators use several methodologies to identify pharmacies that warrant closer attention. Dispensing pattern analysis (which compares a pharmacy’s volume and configuration of controlled substance fills against pharmacies operating in the same geographic and demographic market) is among the most common. A pharmacy filling a disproportionate amount of Schedule II prescriptions relative to its peers, or whose controlled substance volume is concentrated among a narrow set of prescribers, becomes statistically visible.
Prescription drug monitoring program (PDMP) data, which is shared between state authorities and federal investigators, provides another layer of pattern analysis. Referrals from Medicare and Medicaid integrity contractors often precede or accompany DEA inquiries when controlled substance dispensing is billed to federal programs.
Complaints from current or former employees who have observed what they believe to be irregular dispensing activity are another source. State board investigations frequently run alongside or ahead of federal action, and the two tracks are linked: a state board license revocation typically prompts the DEA to request the voluntary surrender of the pharmacy’s DEA registration, and a refusal to surrender leads the DEA to open administrative revocation proceedings. A pharmacy that receives a state board inquiry should treat it as carrying DEA implications regardless of whether the DEA has yet made contact.
Registration Proceedings
The DEA’s primary administrative tool is its authority over pharmacy registrations under 21 U.S.C. § 824. A Show Cause Order initiates a formal proceeding to revoke or suspend a registration and provides the registrant with an opportunity to respond and request a hearing. An Immediate Suspension Order can be issued without prior notice when the DEA concludes that continued operation poses an imminent hazard to public health or safety, taking effect at the moment of service and cutting off the pharmacy’s ability to dispense controlled substances until the matter is resolved. Both proceedings carry automatic reporting consequences to state boards, which retain independent authority to act on the pharmacy’s state license. Permanent revocation of a DEA registration, in the absence of an extraordinary showing, ends the pharmacy’s ability to operate as a controlled substance dispenser.
Criminal liability under 21 U.S.C. § 841 is available when the government can establish that a pharmacist knowingly dispensed outside the authorized course of professional practice. Following Ruan, that requires proof of subjective knowledge rather than an objective “should-have-known” standard. However, lack of documentation, a pattern of filling prescriptions for prescribers who were themselves under investigation, and billing records showing high-volume Schedule II dispensing with no apparent clinical rationale can generate the circumstantial case the government needs.
Building a Compliance Program That Withstands Scrutiny
Pharmacies that have not reviewed their controlled substance compliance programs in the past twelve months should do so to ensure compliance. The review should examine whether the pharmacy has a written policy that addresses red flag identification and the steps required before dispensing proceeds, whether pharmacists are trained on that policy and apply it consistently, and whether the documentation generated at the point of dispensing is retrievable, organized, and legible in a form that would withstand a federal audit.
Recordkeeping compliance is equally important. DEA 222 forms for Schedule II ordering, biennial controlled substance inventory records, PDMP query logs, and drug disposal records are all subject to DEA inspection. Gaps in any of these records, or inconsistencies between ordered quantities and dispensed volumes, can generate adverse findings in an investigation independent of whether the underlying dispensing itself was appropriate. Pharmacies should confirm that these records are complete, accurately reflect actual transactions, and are maintained for the statutorily required periods.
Pharmacies that fill a meaningful volume of prescriptions from a concentrated set of prescribers should evaluate their prescriber base. If a high-volume prescriber for the pharmacy has been the subject of board discipline, press reports, or peer concern regarding prescribing practices, the pharmacy’s own dispensing history in connection with that prescriber may be scrutinized.
Finally, pharmacy owners and pharmacists-in-charge should also have a clear protocol governing what happens when DEA agents arrive unannounced. Pharmacies have the right to understand the purpose and scope of any inspection before consenting to go beyond the administrative inspection authority the DEA holds as a matter of registration. Staff are not required to answer investigator questions without counsel present.
The most effective way to operationalize this is through a written inspection readiness SOP (a short document that identifies who greets the agents, who notifies ownership and counsel, what may be produced on the spot and what should await counsel review, who is authorized to speak on the pharmacy’s behalf, and how the visit is contemporaneously documented). Having legal counsel identified in advance, with a clear internal chain of contact, reduces the risk that an otherwise compliant pharmacy creates a problem for itself in the first hours of a DEA inspection.
Specialty and Oncology Pharmacy Considerations
Specialty pharmacies, particularly those serving oncology, palliative care, and pain management patient populations, face heightened DEA scrutiny that is inherent to the clinical profile of their dispensing.
High-volume filling of Schedule II oral agents in an adult oncology population, or concurrent dispensing of multiple controlled substances for a single patient managing complex symptom burdens, will look statistically unusual when compared with general retail peers. The answer is not to alter dispensing practices but to build the record that explains them.
Specialty pharmacies should maintain documentation of:
- their therapeutic specialization;
- the clinical characteristics of their patient population;
- their prescriber relationships; and
- the rationale for any fills that would appear anomalous in the absence of context.
Pharmacies embedded in or affiliated with physician practices or health systems carry an additional layer of regulatory exposure. In-office dispensing arrangements, captive pharmacy models, and in-house specialty pharmacy operations affiliated with a physician group face scrutiny from both the DEA, which may be attentive to diversion risk in arrangements where prescribers and dispensers are economically aligned, and federal healthcare fraud statutes, including the Anti-Kickback Statute and Stark Law, which impose their own restrictions on those relationships. Pharmacies operating in integrated models should have legal counsel review both their DEA compliance posture and the underlying structure of their prescriber relationships.
How Frier Levitt Can Help
Our team advises independent pharmacies, specialty pharmacies, pharmacy chains, and individual pharmacists on DEA compliance, registration defense, and enforcement response across all stages of federal and state oversight.
We assist clients in:
- designing and implementing controlled substance compliance programs;
- drafting inspection readiness SOPs and training pharmacy staff to execute them if DEA arrives unannounced;
- conducting privileged internal assessments prior to any government inquiry; and
- responding to Show Cause Orders, Immediate Suspension Orders, civil investigative demands, and criminal referrals.
We also advise pharmacies navigating concurrent state board proceedings, counsel pharmacists-in-charge on their individual obligations and rights during inspections, and assist integrated pharmacy operations in evaluating the intersection of DEA compliance with healthcare fraud exposure.
If your pharmacy has received correspondence from the DEA or a state licensing authority, is under inquiry for controlled substance dispensing practices, or has concerns about whether its documentation and recordkeeping would withstand a federal review, we are available to assist.
